Pretreatment serum LDH as additional staging parameter in small-cell lung carcinoma

Stokkel, Marcel P. M.; Eck-Smit, Berthe L. F. van; Zwinderman, A. H.; Willems, L. N. A.; Pauwels, Ekj

doi:10.1016/s0300-2977(97)00080-6

Cited by 5 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high level of serum LDH, a metabolic enzyme detected in patients with several types of malignancies, was identified as a prognostic factor to better stratify patients with SCLC (74). Several studies found a significant relation between serum LDH levels and outcome either in limitedstage and extensive disease SCLC (75,76).…”

Section: Circulating Biomarkersmentioning

confidence: 99%

Are there any theranostic biomarkers in small cell lung carcinoma?

et al. 2019

View full text Add to dashboard Cite

Small cell lung cancer (SCLC), an aggressive lung tumour with a poor prognosis, has a high load of somatic mutations, mainly induced by tobacco carcinogens given the strong association with smoking. Advances in genomic, epigenetic and proteomic profiling have significantly improved our understanding of the molecular and cellular biology of SCLC. Given the high mutational burden of SCLC the immune microenvironment is another exciting area under investigation even if it seems to be quite distinct from that of other solid tumours. In this review we will outline the current progress in molecular etiology of SCLC mentioning some key markers considered promising theranostic biomarkers.

show abstract

Section: Circulating Biomarkersmentioning

confidence: 99%

Are there any theranostic biomarkers in small cell lung carcinoma?

et al. 2019

View full text Add to dashboard Cite

show abstract

The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects

Jurišić

Radenković

Konjević

2015

Advances in Experimental Medicine and Biology

215

112

View full text Add to dashboard Cite

Lactate dehydrogenase (LDH) among many biochemical parameters represents a very valuable enzyme in patients with cancer with possibility for easy routine measurement in many clinical laboratories. Previous studies where mostly based on investigated LDH in serum of patients with cancer with aims to estimate their clinical significance. The new directions in investigation of LDH where based on the principle that tumor cells release intracellular enzymes trough damaged cell membrane, that is mostly consequence in intracellular mitochondrial machinery alteration, and apoptosis deregulation. This consideration can be used not only in-vitro assays, but also in respect to clinical characteristics of tumor patients. Based on new techniques of molecular biology it is shown that intracellular characteristics of LDH enzyme are very sensitive indicators of the cellular metabolic state, aerobic or anaerobic direction of glycolysis, activation status and malignant transformation. Using different molecular analyses it is very useful to analyzed intracellular LDH activity in different cell line and tumor tissues obtained from patients, not only to understanding complexity in cancer biochemistry but also in early clinical diagnosis. Based on understandings of the LDH altered metabolism, new therapy option is created with aims to blocking certain metabolic pathways and stop tumors growth.

show abstract